UNLABELLED: Verruca vulgaris (common warts) is a benign lesion of skin and mucous membranes caused by human papillomavirus (HPV). The lesions are typically self-limited but may vary in size and number. The occurrence on the tongue is extremely rare. To the best of our knowledge, only one verruca vulgaris existing in the tongue had been reported in the literature. CASE PRESENTATION: A rare case of verruca vulgaris of the tongue occurring in a 36-year-old Caucasian male is presented with a discussion on ethiopathogenesis and the treatment methods. Verruca vulgaris must be remembered in the differential diagnosis of tongue lesions and surgical treatment may provide satisfactory outcomes.
UNLABELLED: Verruca vulgaris (common warts) is a benign lesion of skin and mucous membranes caused by human papillomavirus (HPV). The lesions are typically self-limited but may vary in size and number. The occurrence on the tongue is extremely rare. To the best of our knowledge, only one verruca vulgaris existing in the tongue had been reported in the literature. CASE PRESENTATION: A rare case of verruca vulgaris of the tongue occurring in a 36-year-old Caucasian male is presented with a discussion on ethiopathogenesis and the treatment methods. Verruca vulgaris must be remembered in the differential diagnosis of tongue lesions and surgical treatment may provide satisfactory outcomes.
Authors: Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin Journal: Lancet Date: 2006-04-15 Impact factor: 79.321
Authors: G Badaracco; A Venuti; A Di Lonardo; G Scambia; S Mozzetti; P Benedetti Panici; S Mancuso; M L Marcante Journal: J Oral Pathol Med Date: 1998-03 Impact factor: 4.253
Authors: Missy M Clifton; Sandra Marchese Johnson; Paula K Roberson; Jay Kincannon; Thomas D Horn Journal: Pediatr Dermatol Date: 2003 May-Jun Impact factor: 1.588
Authors: S B Jiang; Y S Lu; Y H Zhang; Y Wu; H X Wang; X H Gao; H D Chen Journal: Evid Based Complement Alternat Med Date: 2019-12-31 Impact factor: 2.629